General Toxicity Notes
Blood levels most often the best guide to therapy. Half-life may be prolonged in heart failure or with reduced hepatic blood flow.
Half-Life (Normalesrd) Hours
2-10/No data
Plasma Protein Binding %
>95
Volume Of Distribution L/Kg
3.0
Dose For Normal Renal Function
150 mg q8h
Second Dose
Second Dose: 150-300 mg q8h
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% [A]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
100% [A]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
100% [A]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: None, [A]
Supplement For Dialysis [Recommendation Level]: Pd
PD: None, [A]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Dose for GFR 10-50,[B]
References
Bryson HM, Palmer KJ, Langtry HD, Fitton A. Propafenone. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in cardiac arrhythmias. Drugs. 1993; 45: 85-130. [PMID: 7680987] / Burgess E, Duff H, Wilkes P. Propafenone disposition in renal insufficiency and renal failure. J Clin Pharmacol. 1989; 29: 112-3. [PMID: 2715367] / Fromm MF, Botsch S, Heinkele G, Evers J, Kroemer HK. Influence of renal function on the steady-state pharmacokinetics of the antiarrhythmic propafenone and its phase I and phase II metabolites. Eur J Clin Pharmacol. 1995; 48: 279-83. [PMID: 7589055] / Parker RB, McCollam PL, Bauman JL. Propafenone: a novel type Ic antiarrhythmic agent. DICP. 1989; 23: 196-202. [PMID: 2655298] / Poirier JM, Joannides R, Geffroy-Josse S, Fillastre JP, Etienne I. Propafenone pharmacokinetics in uremic patients treated by peritoneal dialysis [Letter]. Clin Nephrol. 1992; 38: 231-2. [PMID: 1424311] / Seto W, Trope AE, Gow RM. Propafenone disposition during continuous venovenous hemofiltration. Ann Pharmacother. 1999; 33: 957-9. [PMID: 10492500]
Toxicity Notes
Half-life is acetylator phenotype dependent.